|
US6310034B1
(en)
|
1993-05-21 |
2001-10-30 |
Ut-Battelle, Llc |
Agouti polypeptide compositions
|
|
US6001968A
(en)
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
|
US6471956B1
(en)
|
1994-08-17 |
2002-10-29 |
The Rockefeller University |
Ob polypeptides, modified forms and compositions thereto
|
|
US6429290B1
(en)
|
1994-08-17 |
2002-08-06 |
The Rockefeller University |
OB polypeptides, modified forms and derivatives
|
|
US6350730B1
(en)
|
1994-08-17 |
2002-02-26 |
The Rockefeller University |
OB polypeptides and modified forms as modulators of body weight
|
|
US5858967A
(en)
*
|
1995-01-20 |
1999-01-12 |
University Of Washington |
Appetite supression factor and related methods
|
|
US5827734A
(en)
*
|
1995-01-20 |
1998-10-27 |
University Of Washington |
Materials and methods for determining ob protein in a biological sample
|
|
US5552523A
(en)
*
|
1995-01-31 |
1996-09-03 |
Eli Lilly And Company |
Anti-obesity proteins
|
|
US5552522A
(en)
*
|
1995-01-31 |
1996-09-03 |
Eli Lilly And Company |
Anti-obesity proteins
|
|
US5574133A
(en)
*
|
1995-01-31 |
1996-11-12 |
Eli Lilly And Company |
Anti-obesity proteins
|
|
US5567678A
(en)
*
|
1995-01-31 |
1996-10-22 |
Eli Lilly And Company |
Anti-obesity proteins
|
|
US5605886A
(en)
*
|
1995-01-31 |
1997-02-25 |
Eli Lilly And Company |
Anti-obesity proteins
|
|
US5567803A
(en)
*
|
1995-01-31 |
1996-10-22 |
Eli Lilly And Company |
Anti-obesity proteins
|
|
US5691309A
(en)
*
|
1995-01-31 |
1997-11-25 |
Eli Lilly And Company |
Anti-obesity proteins
|
|
US5563243A
(en)
*
|
1995-01-31 |
1996-10-08 |
Eli Lilly And Company |
Anti-obesity proteins
|
|
US5569743A
(en)
*
|
1995-01-31 |
1996-10-29 |
Eli Lilly And Company |
Anti-obesity proteins
|
|
US5559208A
(en)
*
|
1995-01-31 |
1996-09-24 |
Eli Lilly And Company |
Anti-obesity proteins
|
|
US5594104A
(en)
*
|
1995-01-31 |
1997-01-14 |
Eli Lilly And Company |
Anti-obesity proteins
|
|
US5580954A
(en)
*
|
1995-01-31 |
1996-12-03 |
Eli Lilly And Company |
Anti-obesity proteins
|
|
US5554727A
(en)
*
|
1995-01-31 |
1996-09-10 |
Eli Lilly And Company |
Anti-obesity proteins
|
|
EP0725079A1
(en)
*
|
1995-01-31 |
1996-08-07 |
Eli Lilly And Company |
Anti-obesity proteins
|
|
US5563245A
(en)
*
|
1995-01-31 |
1996-10-08 |
Eli Lilly And Company |
Anti-obesity proteins
|
|
US5563244A
(en)
*
|
1995-01-31 |
1996-10-08 |
Eli Lilly And Company |
Anti-obesity proteins
|
|
US5594101A
(en)
*
|
1995-03-03 |
1997-01-14 |
Eli Lilly And Company |
Anti-obesity proteins
|
|
US5719266A
(en)
*
|
1995-03-17 |
1998-02-17 |
Eli Lilly And Company |
Anti-obesity proteins
|
|
EP0736599A3
(en)
*
|
1995-04-03 |
1996-12-11 |
Takeda Chemical Industries Ltd |
The rat obesity gene, its gene product and its production
|
|
AU5098396A
(en)
*
|
1995-04-07 |
1996-10-23 |
Kuyus-Stiftung |
Cosmetic composition for treating cellulite
|
|
US5614379A
(en)
*
|
1995-04-26 |
1997-03-25 |
Eli Lilly And Company |
Process for preparing anti-obesity protein
|
|
US5840517A
(en)
*
|
1995-04-26 |
1998-11-24 |
Eli Lilly And Company |
Process for preparing obesity protein analogs
|
|
GB9509164D0
(en)
*
|
1995-05-05 |
1995-06-28 |
Smithkline Beecham Plc |
Novel compounds
|
|
ZA963530B
(en)
*
|
1995-05-05 |
1996-11-05 |
Hoffmann La Roche |
Recombinant obese (ob) proteins
|
|
DE741187T1
(de)
*
|
1995-05-05 |
1997-04-30 |
Hoffmann La Roche |
Rekombinante Obesitäts-(OB)-Proteine
|
|
EP0826045A1
(en)
*
|
1995-05-08 |
1998-03-04 |
Chiron Corporation |
Nucleic acids for treating obesity
|
|
WO1996036644A1
(en)
*
|
1995-05-19 |
1996-11-21 |
Eli Lilly And Company |
Obesity gene product
|
|
US6395509B1
(en)
|
1995-05-26 |
2002-05-28 |
Eli Lilly And Company |
DNA encoding Rhesus ob protein
|
|
CA2221824A1
(en)
*
|
1995-05-26 |
1996-11-28 |
Eli Lilly And Company |
Rhesus ob protein and dna
|
|
EP0832220A1
(en)
|
1995-06-07 |
1998-04-01 |
Amgen Inc. |
Ob protein compositions and method
|
|
GB9511935D0
(en)
*
|
1995-06-13 |
1995-08-09 |
Smithkline Beecham Plc |
Novel compound
|
|
EP0833835A4
(en)
*
|
1995-06-22 |
1999-05-26 |
Lilly Co Eli |
OBESITY PROTEIN INTERMEDIATE PRODUCTS, THEIR PRODUCTION AND USE
|
|
ZA965346B
(en)
*
|
1995-06-30 |
1997-12-24 |
Lilly Co Eli |
Methods of treating neuropeptide Y-associated conditions.
|
|
EP0759441A3
(en)
*
|
1995-06-30 |
1999-06-30 |
Eli Lilly And Company |
Methods of treating neuropeptide Y-associated conditions
|
|
KR19990028388A
(ko)
*
|
1995-06-30 |
1999-04-15 |
피터 지. 스트링거 |
당뇨병 치료 방법
|
|
DK0865294T3
(da)
*
|
1995-08-17 |
2004-06-28 |
Amgen Inc |
Fremgangsmåder til reduktion eller bibeholdelse af reducerede niveauer afblodlipider under anvendelse af OB-proteinpræparater
|
|
CA2232193A1
(en)
*
|
1995-09-19 |
1997-03-27 |
Brigitte Elisabeth Schoner |
Dna encoding medicinal proteins
|
|
WO1997016550A1
(en)
*
|
1995-11-02 |
1997-05-09 |
Bristol-Myers Squibb Company |
Polypeptide fragments derived from the obese gene product
|
|
US20030040467A1
(en)
|
1998-06-15 |
2003-02-27 |
Mary Ann Pelleymounter |
Ig/ob fusions and uses thereof.
|
|
DE69638119D1
(de)
*
|
1995-11-22 |
2010-03-11 |
Amgen Inc |
Verfahren zur Erhöhung der mageren Fleischmasse mit Fettleibigkeitsprotein (OB) Zusammensetzungen
|
|
US6936439B2
(en)
|
1995-11-22 |
2005-08-30 |
Amgen Inc. |
OB fusion protein compositions and methods
|
|
WO1997020933A2
(en)
*
|
1995-12-06 |
1997-06-12 |
Schering Corporation |
MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS
|
|
US6225446B1
(en)
|
1995-12-06 |
2001-05-01 |
Schering Corporation |
Mutational variants of mammalian proteins
|
|
US6369027B1
(en)
*
|
1995-12-22 |
2002-04-09 |
Amgen Inc. |
Osteoprotegerin
|
|
US7632922B1
(en)
|
1995-12-22 |
2009-12-15 |
Amgen, Inc. |
Osteoprotegerin
|
|
BR9612359A
(pt)
*
|
1995-12-27 |
1999-07-13 |
Genentech Inc |
Derivado covalente de uma proteína ob composição polipeptídeo quimérico sequência de ácido nucleico vetor de express o replicável célula hospedeira e métodos associados aos mesmos
|
|
US6620413B1
(en)
|
1995-12-27 |
2003-09-16 |
Genentech, Inc. |
OB protein-polymer chimeras
|
|
US6541604B1
(en)
|
1996-01-08 |
2003-04-01 |
Genentech, Inc. |
Leptin receptor having a WSX motif
|
|
US20050019325A1
(en)
|
1996-01-08 |
2005-01-27 |
Carter Paul J. |
WSX receptor agonist antibodies
|
|
US7074397B1
(en)
|
1996-01-08 |
2006-07-11 |
Genentech, Inc. |
Method for enhancing proliferation or differentiation of a cell using ob protein
|
|
US6087129A
(en)
|
1996-01-19 |
2000-07-11 |
Betagene, Inc. |
Recombinant expression of proteins from secretory cell lines
|
|
US6110707A
(en)
*
|
1996-01-19 |
2000-08-29 |
Board Of Regents, The University Of Texas System |
Recombinant expression of proteins from secretory cell lines
|
|
EP0877627A1
(en)
*
|
1996-01-25 |
1998-11-18 |
Eli Lilly And Company |
Obesity protein analog compounds and formulations thereof
|
|
EP0912739A2
(en)
*
|
1996-03-01 |
1999-05-06 |
Amgen Inc. |
Canine ob protein compositions and methods
|
|
CA2250570A1
(en)
*
|
1996-03-26 |
1997-10-02 |
Eli Lilly And Company |
Formulations of ob protein
|
|
AU2810497A
(en)
*
|
1996-04-19 |
1997-11-12 |
University Of Washington |
Methods for inducing bone formation
|
|
US6007998A
(en)
*
|
1996-04-22 |
1999-12-28 |
Merck & Co., Inc. |
Leptin assay
|
|
US6025324A
(en)
*
|
1996-05-15 |
2000-02-15 |
Hoffmann-La Roche Inc. |
Pegylated obese (ob) protein compositions
|
|
CA2257140A1
(en)
*
|
1996-06-04 |
1997-12-11 |
The Scripps Research Institute |
Diagnostic and therapeutic methods related to regulating energy mobilization with ob protein and ob antibodies
|
|
AR008765A1
(es)
*
|
1996-06-06 |
2000-02-23 |
Smithkline Beecham Plc |
Un peptido o un derivado, analogo o variante, funcional del mismo, un peptido recombinante o sintetico del mismo, una secuencia nucleotidica y vectorque la contiene, una celula huesped transformada, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un compuesto del
|
|
JP2002514904A
(ja)
*
|
1996-06-20 |
2002-05-21 |
メルク エンド カンパニー インコーポレーテッド |
肥満に対する遺伝子治療
|
|
US6001816A
(en)
*
|
1996-06-20 |
1999-12-14 |
Merck & Co., Inc. |
Gene therapy for leptin deficiency
|
|
US6630346B1
(en)
*
|
1996-06-20 |
2003-10-07 |
Merck & Co., Inc. |
Gene therapy for obesity
|
|
EP0921820A4
(en)
*
|
1996-06-20 |
2003-01-15 |
Merck & Co Inc |
GENETERAPY FOR OBESITY
|
|
US5869037A
(en)
*
|
1996-06-26 |
1999-02-09 |
Cornell Research Foundation, Inc. |
Adenoviral-mediated gene transfer to adipocytes
|
|
US6277592B1
(en)
*
|
1996-07-31 |
2001-08-21 |
Purina Mills, Inc. |
Porcine leptin protein, nucleic acid sequences coding therefor and uses thereof
|
|
US20020110857A1
(en)
*
|
1996-07-31 |
2002-08-15 |
Spurlock Michael E. |
Bovine leptin protein, antisense and antibody
|
|
WO1998008512A1
(en)
*
|
1996-08-30 |
1998-03-05 |
Amgen Inc. |
Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor
|
|
CZ90999A3
(cs)
*
|
1996-09-20 |
1999-06-16 |
Hoechst Aktiengesellschaft |
Farmaceutický přípravek obsahující antagonistu leptinu vhodný pro léčení inzulínové rezistence u diabetes mellitus II. typu
|
|
SE520392C2
(sv)
|
1996-09-27 |
2003-07-01 |
Creative Peptides Sweden Ab C |
Specifika peptider för behandling av diabetes mellitus
|
|
AU4582597A
(en)
*
|
1996-10-11 |
1998-05-11 |
Eli Lilly And Company |
Therapeutic proteins
|
|
UA65549C2
(uk)
|
1996-11-05 |
2004-04-15 |
Елі Ліллі Енд Компані |
Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
|
|
NL1004559C2
(nl)
*
|
1996-11-18 |
1998-05-19 |
Unilife |
Boter.
|
|
WO1998024896A2
(en)
*
|
1996-12-06 |
1998-06-11 |
F. Hoffmann-La Roche Ag |
Muteins of obese protein
|
|
CA2217698A1
(en)
*
|
1996-12-20 |
1998-06-20 |
Eli Lilly And Company |
Anti-obesity proteins
|
|
EP0954588B1
(en)
*
|
1996-12-20 |
2007-01-17 |
Amgen Inc. |
Ob fusion protein compositions and methods
|
|
CA2274799A1
(en)
*
|
1996-12-20 |
1998-07-02 |
Eli Lilly And Company |
Anti-obesity proteins
|
|
EP0973534B1
(en)
*
|
1997-04-15 |
2006-11-02 |
Csir |
Plant extracts having appetite suppressant activity
|
|
US20020019352A1
(en)
*
|
1997-04-17 |
2002-02-14 |
David N. Brems |
Stable, active, human ob protein compositions and methods
|
|
CA2293504A1
(en)
*
|
1997-06-06 |
1998-12-10 |
Valur Emilsson |
Use of leptin antagonists for the treatment of diabetes
|
|
US6017876A
(en)
|
1997-08-15 |
2000-01-25 |
Amgen Inc. |
Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
|
|
ES2590912T3
(es)
|
1997-12-08 |
2016-11-24 |
Merck Patent Gmbh |
Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
|
|
US5866547A
(en)
*
|
1998-01-20 |
1999-02-02 |
Beth Israel Deaconess Medical Center |
Methods of neuroendocrine regulation of affective disorders
|
|
EP0950417A3
(en)
|
1998-02-23 |
2000-02-23 |
Pfizer Products Inc. |
Treatment of skeletal disorders
|
|
US6541033B1
(en)
|
1998-06-30 |
2003-04-01 |
Amgen Inc. |
Thermosensitive biodegradable hydrogels for sustained delivery of leptin
|
|
US6210924B1
(en)
|
1998-08-11 |
2001-04-03 |
Amgen Inc. |
Overexpressing cyclin D 1 in a eukaryotic cell line
|
|
AU770653B2
(en)
*
|
1998-08-12 |
2004-02-26 |
Medical Research Council |
Gene
|
|
US7208572B2
(en)
|
1998-08-21 |
2007-04-24 |
Albany Medical College |
Leptin-related peptides
|
|
US6777388B1
(en)
*
|
1998-08-21 |
2004-08-17 |
Clf Medical Technology Acceleration Program, Inc. |
Leptin-related peptides
|
|
US7056504B1
(en)
|
1998-08-27 |
2006-06-06 |
Massachusetts Institute Of Technology |
Rationally designed heparinases derived from heparinase I and II
|
|
CA2341412A1
(en)
*
|
1998-08-27 |
2000-03-09 |
Massachusetts Institute Of Technology |
Rationally designed heparinases derived from heparinase i and ii
|
|
US6420339B1
(en)
|
1998-10-14 |
2002-07-16 |
Amgen Inc. |
Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
|
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
ATE348163T1
(de)
|
1998-10-23 |
2007-01-15 |
Amgen Inc |
Thrombopoietin substitute
|
|
US7488590B2
(en)
|
1998-10-23 |
2009-02-10 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
US6245740B1
(en)
|
1998-12-23 |
2001-06-12 |
Amgen Inc. |
Polyol:oil suspensions for the sustained release of proteins
|
|
CA2360347C
(en)
|
1998-12-31 |
2013-05-07 |
Chiron Corporation |
Improved expression of hiv polypeptides and production of virus-like particles
|
|
CZ20012406A3
(cs)
*
|
1999-01-07 |
2002-03-13 |
Lexigen Pharmaceuticals, Corp. |
Exprese a export proteinů působících proti obezitě jako Fc fúzních proteinů
|
|
ATE323766T1
(de)
*
|
1999-02-12 |
2006-05-15 |
Amgen Inc |
Glykosylierte leptinzusammensetzungen und zugehörige verfahren
|
|
WO2000056903A2
(en)
*
|
1999-03-22 |
2000-09-28 |
Zymogenetics, Inc. |
IMPROVED METHODS FOR PRODUCING PROTEINS IN TRANSFORMED $i(PICHIA)
|
|
US20050272652A1
(en)
|
1999-03-29 |
2005-12-08 |
Gault Victor A |
Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
|
|
CA2370539C
(en)
*
|
1999-04-23 |
2009-01-06 |
Massachusetts Institute Of Technology |
System and method for notating polymers
|
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
US7160924B2
(en)
|
2002-07-19 |
2007-01-09 |
The General Hospital Corporation |
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
|
|
DE60025832T2
(de)
|
1999-08-09 |
2006-08-31 |
Emd Lexigen Research Center Corp., Billerica |
Mehrere zytokin-antikörper komplexen
|
|
US8106098B2
(en)
|
1999-08-09 |
2012-01-31 |
The General Hospital Corporation |
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
|
|
GB2396815B
(en)
*
|
1999-10-27 |
2004-09-08 |
Phytopharm Plc |
A composition comprising a pregnenone derivative and an NSAID
|
|
CA2391080A1
(en)
|
1999-11-12 |
2001-05-25 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Erythropoietin forms with improved properties
|
|
CN1406249B
(zh)
|
2000-02-11 |
2010-06-16 |
默克专利股份有限公司 |
增加基于抗体的融合蛋白的循环半衰期
|
|
JP2003525946A
(ja)
*
|
2000-03-08 |
2003-09-02 |
マサチューセッツ インスティテュート オブ テクノロジー |
ヘパリナーゼiiiおよびその使用
|
|
ES2260219T3
(es)
|
2000-04-21 |
2006-11-01 |
Amgen Inc. |
Derivados de peptidos apo-ai/aii.
|
|
US6677136B2
(en)
|
2000-05-03 |
2004-01-13 |
Amgen Inc. |
Glucagon antagonists
|
|
PT1294401E
(pt)
|
2000-06-29 |
2007-11-09 |
Merck Patent Gmbh |
Aumento das respostas imunológicas mediadas por proteínas de fusão anticorpo-citoquina por tratamento combinado com agentes que aumentam a captação de imunocitoquinas
|
|
GB2363985B
(en)
*
|
2000-06-30 |
2004-09-29 |
Phytopharm Plc |
Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
|
|
US6443013B1
(en)
*
|
2000-08-04 |
2002-09-03 |
Samsung Electronics Co., Ltd. |
Rotary test fixture
|
|
BR0107175A
(pt)
*
|
2000-09-04 |
2002-07-02 |
Hyo Joon Kim |
Peptìdeos miméticos para epitopo de apolipoproteìna b-100, concatemero e seus peptìdeos modificados, e composição de vacina compreendendo os mesmos
|
|
DK1319183T3
(da)
|
2000-09-12 |
2009-05-18 |
Massachusetts Inst Technology |
Fremgangsmåder og produkter relateret til heparin med lav molekylvægt
|
|
EP1328260A2
(en)
|
2000-10-18 |
2003-07-23 |
Massachusetts Institute Of Technology |
Methods and products related to pulmonary delivery of polysaccharides
|
|
US7054758B2
(en)
|
2001-01-30 |
2006-05-30 |
Sciona Limited |
Computer-assisted means for assessing lifestyle risk factors
|
|
EP1998266A3
(en)
|
2001-02-19 |
2009-02-11 |
Merck Patent GmbH |
Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity
|
|
RU2003129528A
(ru)
|
2001-03-07 |
2005-04-10 |
Мерк Патент ГмбХ (DE) |
Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
|
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
|
CN100503639C
(zh)
|
2001-05-03 |
2009-06-24 |
默克专利有限公司 |
重组肿瘤特异性抗体及其应用
|
|
ATE549354T1
(de)
|
2001-05-11 |
2012-03-15 |
Amgen Inc |
Peptide und damit zusammenhängende an tall-1 bindende moleküle
|
|
US20030124196A1
(en)
*
|
2001-08-22 |
2003-07-03 |
Susan Weinbach |
Pulsatile release compositions and methods for enhanced intestinal drug absorption
|
|
US20030083286A1
(en)
*
|
2001-08-22 |
2003-05-01 |
Ching-Leou Teng |
Bioadhesive compositions and methods for enhanced intestinal drug absorption
|
|
DE10145553B4
(de)
*
|
2001-09-16 |
2006-06-08 |
Gene Architects Ag |
Nukleinsäure für einen Klonierungsvektor
|
|
US9969980B2
(en)
|
2001-09-21 |
2018-05-15 |
Garnet Biotherapeutics |
Cell populations which co-express CD49c and CD90
|
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
|
ES2350924T3
(es)
|
2001-10-22 |
2011-01-28 |
Amgen, Inc. |
Uso de leptina para el tratamiento de la lipoatrofia humana y método para determinar la predisposición a dicho tratamiento.
|
|
WO2003039454A2
(en)
|
2001-10-23 |
2003-05-15 |
Oklahoma Medical Research Foundation |
Beta-secretase inhibitors and methods of use
|
|
EP2354791A1
(en)
|
2001-12-04 |
2011-08-10 |
Merck Patent GmbH |
Immunocytokines with modulated selectivity
|
|
WO2003059988A2
(en)
|
2002-01-14 |
2003-07-24 |
The General Hospital Corporation |
Biodegradable polyketal polymers and methods for their formation and use
|
|
US20030191056A1
(en)
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
|
CA2387003A1
(en)
*
|
2002-05-21 |
2003-11-21 |
984012 Alberta Ltd. |
Method for improving efficiencies in livestock production
|
|
AU2003254023A1
(en)
|
2002-07-19 |
2004-02-09 |
The General Hospital Corporation |
Oxime conjugates and methods for their formation and use
|
|
JP2006508056A
(ja)
|
2002-08-28 |
2006-03-09 |
イミュネックス・コーポレーション |
心臓血管疾患を治療するための組成物および方法
|
|
PT1572748E
(pt)
|
2002-12-17 |
2010-09-28 |
Merck Patent Gmbh |
Anticorpo humanizado (h14.18) do anticorpo 14.18 de rato que se liga ao gd2 e a sua fusão com a il-2
|
|
US8491883B2
(en)
|
2003-06-27 |
2013-07-23 |
Advanced Technologies And Regenerative Medicine, Llc |
Treatment of amyotrophic lateral sclerosis using umbilical derived cells
|
|
US8790637B2
(en)
|
2003-06-27 |
2014-07-29 |
DePuy Synthes Products, LLC |
Repair and regeneration of ocular tissue using postpartum-derived cells
|
|
AU2004252571C1
(en)
|
2003-06-27 |
2012-03-01 |
Ethicon, Incorporated |
Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
|
|
US9572840B2
(en)
|
2003-06-27 |
2017-02-21 |
DePuy Synthes Products, Inc. |
Regeneration and repair of neural tissue using postpartum-derived cells
|
|
US9592258B2
(en)
|
2003-06-27 |
2017-03-14 |
DePuy Synthes Products, Inc. |
Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
|
|
US7875272B2
(en)
|
2003-06-27 |
2011-01-25 |
Ethicon, Incorporated |
Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
|
|
ES2383328T3
(es)
|
2003-07-25 |
2012-06-20 |
Amgen, Inc |
Métodos relacionados con LDCAM y CRTAM
|
|
JP4585186B2
(ja)
*
|
2003-07-31 |
2010-11-24 |
杏林製薬株式会社 |
肥満、糖尿病及び脂質代謝異常の新規な予防又は治療剤
|
|
JP5537763B2
(ja)
|
2003-09-05 |
2014-07-02 |
ザ ジェネラル ホスピタル コーポレイション |
放出システムとしてのポリアセタール薬物抱合体
|
|
WO2005042475A2
(en)
|
2003-10-21 |
2005-05-12 |
Sention, Inc. |
Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
|
|
DE10352510A1
(de)
*
|
2003-11-07 |
2005-06-23 |
Forschungsinstitut Für Die Biologie Landwirtschaftlicher Nutztiere |
Verfahren zur Identifizierung von Wirkstoffen zur Beeinflussung der Körpermasse und des Fettansatzes
|
|
AU2004313245B2
(en)
|
2003-12-30 |
2011-04-14 |
Durect Corporation |
Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents, preferably a GNRH
|
|
IN2012DN03921A
(es)
|
2004-02-11 |
2015-09-04 |
Amylin Pharmaceuticals Inc |
|
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
|
JP2008505928A
(ja)
|
2004-07-08 |
2008-02-28 |
アムジェン インコーポレーテッド |
治療用ペプチド
|
|
US20090233986A1
(en)
*
|
2004-07-27 |
2009-09-17 |
Mount Sinai School Of Medicine |
Methods and compositions for using sax2
|
|
JP2008513497A
(ja)
|
2004-09-17 |
2008-05-01 |
コメンティス,インコーポレーテッド |
メマプシン2βセクレターゼ活性を阻害するアミノ含有化合物およびその使用方法
|
|
KR101441026B1
(ko)
|
2004-09-24 |
2014-10-01 |
메소블라스트, 아이엔씨. |
증폭된 다능성 간엽 전구세포 자손 및 이의 용도
|
|
DK1797127T3
(en)
|
2004-09-24 |
2017-10-02 |
Amgen Inc |
Modified Fc molecules
|
|
CA2581237C
(en)
|
2004-09-24 |
2018-11-06 |
Angioblast Systems, Inc. |
Method of enhancing proliferation and/or survival of mesenchymal precursor cells (mpc)
|
|
US8394765B2
(en)
|
2004-11-01 |
2013-03-12 |
Amylin Pharmaceuticals Llc |
Methods of treating obesity with two different anti-obesity agents
|
|
CA2584806C
(en)
|
2004-11-01 |
2014-06-17 |
Amylin Pharmaceuticals, Inc. |
Treatment of obesity and related disorders
|
|
EP1812038A1
(en)
|
2004-11-18 |
2007-08-01 |
VIB vzw |
Fibronectin iii domain as leptin receptor antagonists
|
|
US7307142B2
(en)
*
|
2004-11-26 |
2007-12-11 |
Yissum Research And Development Company Of The Hebrew University Of Jerusalem |
Leptin antagonists
|
|
WO2006071802A2
(en)
|
2004-12-23 |
2006-07-06 |
Ethicon Incorporated |
Treatment of stroke and other acute neural degenerative disorders using postpartum derived cells
|
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
|
WO2006086769A2
(en)
|
2005-02-11 |
2006-08-17 |
Amylin Pharmaceuticals, Inc. |
Gip analog and hybrid polypeptides with selectable properties
|
|
CA2604291A1
(en)
|
2005-04-08 |
2006-10-19 |
Comentis, Inc. |
Compounds which inhibit beta-secretase activity and methods of use thereof
|
|
KR101446634B1
(ko)
|
2005-04-12 |
2014-10-16 |
메소블라스트, 아이엔씨. |
조직 비특이적인 알카리 포스파타제에 의한 다분화성 성체세포의 분리
|
|
US7833979B2
(en)
|
2005-04-22 |
2010-11-16 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
|
AU2006279680B2
(en)
|
2005-08-11 |
2012-12-06 |
Amylin Pharmaceuticals, Llc |
Hybrid polypeptides with selectable properties
|
|
EP2330125A3
(en)
|
2005-08-11 |
2012-12-12 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
|
US8227408B2
(en)
*
|
2005-09-07 |
2012-07-24 |
Neurotez, Inc. |
Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
|
|
CA2626082C
(en)
|
2005-10-13 |
2017-04-11 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
|
TW200736277A
(en)
|
2005-11-14 |
2007-10-01 |
Amgen Inc |
RANKL antibody-PTH/PTHrP chimeric molecules
|
|
PL1971681T3
(pl)
|
2005-12-16 |
2018-01-31 |
Depuy Synthes Products Inc |
Kompozycje oraz sposoby do hamowania niepożądanej odpowiedzi immunologicznej w przypadku transplantacji z brakiem zgodności tkankowej
|
|
US9125906B2
(en)
|
2005-12-28 |
2015-09-08 |
DePuy Synthes Products, Inc. |
Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
|
|
ES2555544T3
(es)
|
2006-03-07 |
2016-01-04 |
Vaxinnate Corporation |
Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
|
|
JO3324B1
(ar)
|
2006-04-21 |
2019-03-13 |
Amgen Inc |
مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
|
|
CN103255162A
(zh)
|
2006-05-19 |
2013-08-21 |
格利科菲公司 |
促红细胞生成素组合物
|
|
US20080096900A1
(en)
|
2006-06-26 |
2008-04-24 |
Amgen Inc. |
Methods for treating atherosclerosis
|
|
US8778977B2
(en)
|
2006-06-30 |
2014-07-15 |
Sunesis Pharmaceuticals, Inc. |
Pyridinonyl PDK1 inhibitors
|
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
|
TW200833840A
(en)
|
2006-10-25 |
2008-08-16 |
Amgen Inc |
Toxin peptide therapeutic agents
|
|
JP2010510314A
(ja)
|
2006-11-22 |
2010-04-02 |
シーサイド セラピューティクス,エルエルシー |
精神遅滞、ダウン症候群、脆弱x症候群および自閉症の治療方法
|
|
EP2738257A1
(en)
|
2007-05-22 |
2014-06-04 |
Amgen Inc. |
Compositions and methods for producing bioactive fusion proteins
|
|
JP5658031B2
(ja)
|
2007-06-22 |
2015-01-21 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
薄膜凍結による安定したサブミクロンのペプチド又はタンパク質粒子の形成
|
|
PL2489731T3
(pl)
|
2007-07-26 |
2015-01-30 |
Amgen Inc |
Zmodyfikowane enzymy acylotransferaza lecytyna-cholesterol
|
|
MX2010002938A
(es)
|
2007-09-24 |
2010-04-01 |
Comentis Inc |
Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
|
|
AU2009236585B2
(en)
|
2008-04-18 |
2013-03-07 |
Vaxinnate Corporation |
Deletion mutants of flagellin and methods of use
|
|
AU2009248914A1
(en)
*
|
2008-05-21 |
2009-11-26 |
Neurotez, Inc. |
Methods for Treating Neurodegenerative Disorders Related to Neurofibrillary Tangles
|
|
CN102105146A
(zh)
|
2008-05-23 |
2011-06-22 |
国立犹太保健医院 |
用于治疗与暴露于烷化物质有关的损伤的方法
|
|
US8501686B2
(en)
|
2008-06-05 |
2013-08-06 |
University Of Michigan |
Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects
|
|
EP2671891A3
(en)
|
2008-06-27 |
2014-03-05 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
|
CN104230901A
(zh)
|
2008-09-15 |
2014-12-24 |
加利福尼亚大学董事会 |
用于调节ire1、src和abl活性的方法和组合物
|
|
CN102281865B
(zh)
|
2008-10-15 |
2017-04-05 |
精达制药公司 |
高浓缩药物颗粒、制剂、混悬剂及其应用
|
|
US8143347B2
(en)
|
2008-10-15 |
2012-03-27 |
Baxter International Inc. |
Pegylation of recombinant blood coagulation factors in the presence of bound antibodies
|
|
KR20120024529A
(ko)
*
|
2008-11-04 |
2012-03-14 |
니콜라오스 테자프시디스 |
신경섬유 매듭 및 아밀로이드 베타의 축적으로부터 기인하는 진행성 인지 기능 장애의 치료용 렙틴 조성물 및 치료 방법
|
|
US8491880B2
(en)
|
2008-12-10 |
2013-07-23 |
Mersana Therapeutics, Inc. |
Pharmaceutical formulations of biodegradable biocompatible camptothecin-polymer conjugates
|
|
PL2379088T3
(pl)
|
2008-12-19 |
2018-07-31 |
DePuy Synthes Products, Inc. |
Leczenie płuca oraz chorób i zaburzeń płucnych
|
|
PT2379087E
(pt)
|
2008-12-19 |
2014-12-02 |
Depuy Synthes Products Llc |
Células derivadas do tecido do cordão umbilical para o tratamento da dor neuropática e espasticidade
|
|
US10179900B2
(en)
|
2008-12-19 |
2019-01-15 |
DePuy Synthes Products, Inc. |
Conditioned media and methods of making a conditioned media
|
|
EA020843B1
(ru)
|
2009-02-03 |
2015-02-27 |
Амуникс Оперейтинг Инк. |
Удлиненные рекомбинантные полипептиды и содержащие их композиции
|
|
BRPI1013409A2
(pt)
|
2009-03-26 |
2018-01-16 |
Advanced Tech And Regenerative Medicine Llc |
células de tecido de cordão umbilical humano como terapia para doença de alzheimer
|
|
US20120071401A1
(en)
|
2009-04-10 |
2012-03-22 |
Amylin Pharamaceuticals, Inc. |
Amylin agonist compounds for estrogen-deficient mammals
|
|
BRPI1014942A2
(pt)
|
2009-06-19 |
2019-09-24 |
Medimmune Llc |
"polipeptídeo, ácido nucleico, vetor, célula hospedeira, método para produzir um polipeptídeo, composição farmacêutica, e método para tratar uma doença"
|
|
EP3205647B1
(en)
|
2009-08-17 |
2020-05-13 |
Memorial Sloan-Kettering Cancer Center |
2-(pyrimidin-5-yl)-thiopyrimidine derivatives as hsp70 and hsc70 modulators for the treatment of proliferative disorders
|
|
WO2011029043A1
(en)
|
2009-09-04 |
2011-03-10 |
Biogen Idec Ma Inc. |
Heteroaryl btk inhibitors
|
|
EP3461824B1
(en)
|
2009-09-04 |
2021-08-25 |
Biogen MA Inc. |
Bruton's tyrosine kinase inhibitors
|
|
CN102665718B
(zh)
|
2009-10-06 |
2016-03-09 |
米伦纽姆医药公司 |
可用作pdk1抑制剂的杂环化合物
|
|
CA2780205A1
(en)
|
2009-11-05 |
2011-05-12 |
Brown University |
Methods of treating elevations in mtor signaling
|
|
US20110136728A1
(en)
*
|
2009-12-09 |
2011-06-09 |
Patricia Grasso |
Methods of increasing bone formation using leptin-related peptides
|
|
MX347591B
(es)
|
2009-12-10 |
2017-05-03 |
The Regents Of The Univ Of California * |
Agentes de enlace amiloides.
|
|
RU2639876C2
(ru)
|
2010-03-30 |
2017-12-25 |
Версеон Корпорейшн |
Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
|
|
CN101812450B
(zh)
*
|
2010-04-28 |
2012-01-11 |
中国农业大学 |
辅助鉴定具有不同体重性状鸡的方法及其专用引物
|
|
CA2813087C
(en)
|
2010-09-28 |
2020-07-21 |
Amylin Pharmaceuticals, Llc |
Engineered polypeptides having enhanced duration of action
|
|
EP2632898A4
(en)
|
2010-10-29 |
2014-04-02 |
Biogen Idec Inc |
HETEROCYCLIC TYROSINE KINASE HEMMER
|
|
RU2599249C2
(ru)
|
2011-02-14 |
2016-10-10 |
Аллерган, Инк. |
Композиции и способы применения сложноэфирных производных биматопроста
|
|
CA2836449C
(en)
|
2011-05-17 |
2021-04-27 |
The Regents Of The University Of California |
Kinase inhibitors
|
|
EP2714069A4
(en)
|
2011-05-25 |
2015-06-24 |
Amylin Pharmaceuticals Llc |
LONG-TERM CONJUGATES WITH TWO HORMONES
|
|
WO2012174484A2
(en)
*
|
2011-06-15 |
2012-12-20 |
Nse Products, Inc. |
Identifying markers of caloric restriction and caloric restriction mimetics
|
|
DK2729160T3
(da)
|
2011-07-08 |
2019-07-01 |
Aegerion Pharmaceuticals Inc |
Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet
|
|
AU2011374879C1
(en)
|
2011-08-10 |
2018-06-14 |
DePuy Synthes Products, Inc. |
Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
|
|
MX370814B
(es)
|
2011-09-02 |
2020-01-08 |
Univ California |
Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
|
|
US9073851B2
(en)
|
2011-10-28 |
2015-07-07 |
Board Of Regents, The University Of Texas System |
Compositions and methods for treating cancer
|
|
MX362198B
(es)
|
2011-12-23 |
2019-01-08 |
Depuy Synthes Products Llc |
Deteccion de celulas derivadas de tejido de cordon umbilical humano.
|
|
CN104379563B
(zh)
|
2012-04-10 |
2018-12-21 |
加利福尼亚大学董事会 |
用于治疗癌症的组合物和方法
|
|
EP2858500A4
(en)
|
2012-06-08 |
2016-04-06 |
Biogen Ma Inc |
BRUTON TYROSINE KINASE HEMMER
|
|
AR091273A1
(es)
|
2012-06-08 |
2015-01-21 |
Biogen Idec Inc |
Inhibidores de pirimidinil tirosina quinasa
|
|
WO2013188452A1
(en)
|
2012-06-11 |
2013-12-19 |
The Regents Of The University Of California |
Compounds and methods of treating cancer
|
|
US9090595B2
(en)
|
2012-08-27 |
2015-07-28 |
Allergan, Inc. |
Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
|
|
CN104684904B
(zh)
|
2012-08-27 |
2017-10-13 |
阿勒根公司 |
通过使用β‑氯环戊烷的亲水性酯前药减轻中央角膜增厚
|
|
US8932598B2
(en)
|
2012-08-28 |
2015-01-13 |
Vaxinnate Corporation |
Fusion proteins and methods of use
|
|
AU2013323426A1
(en)
|
2012-09-26 |
2015-04-23 |
The Regents Of The University Of California |
Modulation of ire1
|
|
CN111529534A
(zh)
|
2012-09-27 |
2020-08-14 |
儿童医学中心公司 |
用于治疗肥胖症的化合物和其使用方法
|
|
US9364462B2
(en)
|
2012-10-30 |
2016-06-14 |
The Regents Of The University Of California |
Alpha-1-adrenergic receptor agonist therapy
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
EP2953475B1
(en)
|
2013-02-06 |
2019-07-03 |
Celgene Corporation |
Modified t lymphocytes having improved specificity
|
|
CA2903827C
(en)
|
2013-03-14 |
2021-08-10 |
Stefan Oscarson |
Thiosaccharide mucolytic agents
|
|
UY35464A
(es)
|
2013-03-15 |
2014-10-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
|
MX373964B
(es)
|
2013-03-15 |
2020-07-13 |
Verseon Corp |
Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
|
|
HK1220205A1
(zh)
|
2013-03-15 |
2017-04-28 |
Celgene Corporation |
修饰的t淋巴细胞
|
|
CA2901529A1
(en)
|
2013-03-15 |
2014-09-18 |
Allergan, Inc. |
Bimatoprost for enhancement of leptin production
|
|
TWI642677B
(zh)
|
2013-03-15 |
2018-12-01 |
美國加利福尼亞大學董事會 |
非環狀核苷膦酸二酯
|
|
US9951025B2
(en)
|
2013-03-15 |
2018-04-24 |
Verseon Corporation |
Halogenopyrazoles as inhibitors of thrombin
|
|
CA2917527C
(en)
|
2013-07-15 |
2022-06-14 |
Board Of Regents, The University Of Texas System |
Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain
|
|
PT3035926T
(pt)
|
2013-08-19 |
2020-09-01 |
Univ California |
Compostos e métodos para tratar um distúrbio epiléptico
|
|
WO2015031799A1
(en)
|
2013-08-30 |
2015-03-05 |
The Regents Of The University Of California, A California Corporation |
Scintillator nanocrystal-containing compositions and methods for their use
|
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Kras g12c之抑制劑
|
|
JP6672157B2
(ja)
|
2013-11-26 |
2020-03-25 |
ザ チルドレンズ メディカル センター コーポレーション |
肥満を処置するための化合物およびその使用方法
|
|
SI3080103T1
(sl)
|
2013-12-11 |
2018-11-30 |
Biogen Ma Inc. |
Biarilne spojine, ki so uporabne za zdravljenje človeških bolezni na področju onkologije, nevrologije in imunologije
|
|
WO2015089327A1
(en)
|
2013-12-11 |
2015-06-18 |
Biogen Idec Ma Inc. |
Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
|
|
EP3086792B1
(en)
|
2013-12-23 |
2022-10-12 |
Memorial Sloan-Kettering Cancer Center |
Methods and reagents for radiolabeling
|
|
MX374517B
(es)
|
2014-01-15 |
2025-03-06 |
Medimmune Ltd |
Anticuerpos especificos del virus respiratorio sincitial (vrs) y partes funcionales de los mismos.
|
|
CA2939569A1
(en)
|
2014-02-20 |
2015-11-19 |
Allergan, Inc. |
Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
|
|
US20170209408A1
(en)
|
2014-04-03 |
2017-07-27 |
The Children's Medical Center Corporation |
Hsp90 inhibitors for the treatment of obesity and methods of use thereof
|
|
EP3143013B1
(en)
|
2014-05-13 |
2019-12-18 |
Memorial Sloan Kettering Cancer Center |
Hsp70 modulators and methods for making and using the same
|
|
WO2016004383A1
(en)
|
2014-07-03 |
2016-01-07 |
City Of Hope |
Tumor-selective ctla-4 antagonists
|
|
CA2957929A1
(en)
|
2014-08-12 |
2016-02-18 |
Anthrogenesis Corporation |
Car-t lymphocytes engineered to home to lymph node b cell zone, skin, or gastrointestinal tract
|
|
EA036391B1
(ru)
|
2014-09-15 |
2020-11-05 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния |
Нуклеотидные аналоги
|
|
US10189810B2
(en)
|
2014-09-17 |
2019-01-29 |
Verseon Corporation |
Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
US9862701B2
(en)
|
2014-09-25 |
2018-01-09 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2016049568A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Methods and compositions for inhibition of ras
|
|
CN111978310A
(zh)
|
2014-10-02 |
2020-11-24 |
阿勒根公司 |
γ-内酰胺的酯前药及其用途
|
|
WO2016115275A1
(en)
|
2015-01-13 |
2016-07-21 |
City Of Hope |
Ctla4-binding protein peptide-linker masks
|
|
CA3204599A1
(en)
|
2015-02-25 |
2016-09-01 |
The Regents Of The University Of California |
5ht agonists for treating disorders
|
|
AU2016224975B2
(en)
|
2015-02-27 |
2020-10-22 |
The Regents Of The University Of California |
Small molecules that enable cartilage rejuvanation
|
|
SI3261639T1
(sl)
|
2015-02-27 |
2023-01-31 |
Verseon International Corporation |
Substituirane pirazolne spojine kot zaviralci serinskih proteaz
|
|
EA201792214A1
(ru)
|
2015-04-10 |
2018-01-31 |
Араксис Фарма Ллк |
Соединения замещенного хиназолина
|
|
JP6789239B2
(ja)
|
2015-04-15 |
2020-11-25 |
アラクセス ファーマ エルエルシー |
Krasの縮合三環系インヒビターおよびその使用の方法
|
|
AU2016247858B2
(en)
|
2015-04-17 |
2020-10-15 |
Ludwig Institute For Cancer Research Ltd. |
PLK4 inhibitors
|
|
MA42510A
(fr)
|
2015-06-10 |
2018-06-06 |
Biogen Ma Inc |
Formes et compositions d'inhibiteurs biaryles de la tyrosine kinase de bruton
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
MX2021006326A
(es)
|
2015-09-17 |
2022-12-16 |
|
Inhibidores de pcna.
|
|
CN105132566A
(zh)
*
|
2015-09-21 |
2015-12-09 |
上海中优生物高科技有限责任公司 |
毒素堆积型肥胖基因个体化干预饮品的制备方法及其系统
|
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356354A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
US10689356B2
(en)
|
2015-09-28 |
2020-06-23 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
US10882847B2
(en)
|
2015-09-28 |
2021-01-05 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3359647A1
(en)
|
2015-10-08 |
2018-08-15 |
Neurona Therapeutics Inc. |
Neural precursor cell populations and uses thereof
|
|
TWI752920B
(zh)
|
2015-10-12 |
2022-01-21 |
美商再生元醫藥公司 |
活化瘦素受體的抗原結合蛋白
|
|
EP3364977A4
(en)
|
2015-10-19 |
2019-09-04 |
Araxes Pharma LLC |
PROCESS FOR SCREENING INHIBITORS OF RAS
|
|
JP7034078B2
(ja)
|
2015-10-23 |
2022-03-11 |
イーアールエックス ファーマシューティカルズ インコーポレイテッド |
セラストロールの類似体
|
|
CN108697699A
(zh)
|
2015-10-23 |
2018-10-23 |
苏尼西斯制药有限公司 |
用于治疗癌症的杂环pdk1抑制剂
|
|
CA3005089A1
(en)
|
2015-11-16 |
2017-05-26 |
Araxes Pharma Llc |
2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
|
|
US9988357B2
(en)
|
2015-12-09 |
2018-06-05 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
|
BR112018012934B1
(pt)
|
2015-12-24 |
2023-11-07 |
The Regents Of The University Of California |
Reguladores cftr e métodos de uso dos mesmos
|
|
AU2016379444B2
(en)
|
2015-12-24 |
2021-04-29 |
The Regents Of The University Of California |
CFTR regulators and methods of use thereof
|
|
US11834675B2
(en)
|
2015-12-30 |
2023-12-05 |
Celgene Corporation |
T lymphocyte production methods and t lymphocytes produced thereby
|
|
US10822312B2
(en)
|
2016-03-30 |
2020-11-03 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
|
PL3458448T3
(pl)
|
2016-04-25 |
2021-12-06 |
Forma Therapeutics, Inc. |
Inhibitory fasn do zastosowania w leczeniu niealkoholowego stłuszczeniowego zapalenia wątroby
|
|
US20210323913A1
(en)
|
2016-04-29 |
2021-10-21 |
Board Of Regents, The University Of Texas System |
Sigma receptor binders
|
|
EP3578562B1
(en)
|
2016-05-12 |
2021-06-23 |
Anacor Pharmaceuticals, Inc |
L-valinate amide benzoxaborole derivatives for the treatment of parasitic diseases
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
US11174243B2
(en)
|
2016-07-21 |
2021-11-16 |
Sunesis Pharmaceuticals, Inc. |
Succinate forms and compositions of Bruton's tyrosine kinase inhibitors
|
|
MX2019000962A
(es)
|
2016-07-26 |
2019-08-01 |
Biomarin Pharm Inc |
Novedosas proteinas de la capside del virus adenoasociado.
|
|
US11542261B2
(en)
|
2016-08-17 |
2023-01-03 |
Children's Hospital Medical Center |
Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
|
|
US11254667B2
(en)
|
2016-08-17 |
2022-02-22 |
Children's Hospital Medical Center |
Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors
|
|
ES2959990T3
(es)
|
2016-09-12 |
2024-02-29 |
Amryt Pharmaceuticals Inc |
Métodos de detección de anticuerpos neutralizantes dirigidos contra la leptina
|
|
JP2019529484A
(ja)
|
2016-09-29 |
2019-10-17 |
アラクセス ファーマ エルエルシー |
Kras g12c変異体タンパク質の阻害剤
|
|
CN110312711A
(zh)
|
2016-10-07 |
2019-10-08 |
亚瑞克西斯制药公司 |
作为ras抑制剂的杂环化合物及其使用方法
|
|
EP4092049A1
(en)
|
2016-10-20 |
2022-11-23 |
Celgene Corporation |
Cereblon-based heterodimerizable chimeric antigen receptors
|
|
AU2017378487B2
(en)
|
2016-12-15 |
2022-03-31 |
The Regents Of The University Of California |
Compositions and methods for treating cancer
|
|
EP3573971A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
|
JP7327802B2
(ja)
|
2017-01-26 |
2023-08-16 |
アラクセス ファーマ エルエルシー |
縮合ヘテロ-ヘテロ二環式化合物およびその使用方法
|
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
US11274093B2
(en)
|
2017-01-26 |
2022-03-15 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
JP2020521740A
(ja)
|
2017-05-25 |
2020-07-27 |
アラクセス ファーマ エルエルシー |
変異体kras、hrasまたはnrasの調節因子としてのキナゾリン誘導体
|
|
US10745385B2
(en)
|
2017-05-25 |
2020-08-18 |
Araxes Pharma Llc |
Covalent inhibitors of KRAS
|
|
TW201906832A
(zh)
|
2017-05-25 |
2019-02-16 |
美商亞瑞克西斯製藥公司 |
用於癌症治療之化合物及其使用方法
|
|
CN107385020A
(zh)
*
|
2017-06-23 |
2017-11-24 |
西安医学院 |
瘦素在人重组fgf21蛋白活性检测中的应用
|
|
US11260048B2
(en)
|
2017-10-03 |
2022-03-01 |
The Schepens Eye Research Institute, Inc. |
Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same
|
|
BR112020007204A2
(pt)
|
2017-10-10 |
2021-02-02 |
Syros Pharmaceuticals, Inc. |
compostos de pirrolotriazina e métodos de inibir tam quinases
|
|
CA3088526A1
(en)
|
2018-01-16 |
2019-07-25 |
Syros Pharmaceuticals, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
CN112135825A
(zh)
|
2018-03-13 |
2020-12-25 |
夏尔人类遗传性治疗公司 |
血浆激肽释放酶抑制剂及其用途
|
|
SI3773713T1
(sl)
|
2018-04-06 |
2025-08-29 |
Regeneron Pharmaceuticals, Inc. |
Protitelo, agonist leptinskega receptorja, za uporabo pri povečanju kostne mase pri osebi, ki trpi zaradi presnovne disfunkcije ali hipoleptinemije
|
|
WO2019217513A2
(en)
|
2018-05-09 |
2019-11-14 |
Biomarin Pharmaceutical Inc. |
Methods of treating phenylketonuria
|
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
|
BR112021001709A2
(pt)
|
2018-08-01 |
2021-05-04 |
Araxes Pharma Llc |
compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
|
|
WO2020055916A1
(en)
|
2018-09-10 |
2020-03-19 |
The Regents Of The University Of California |
Dithiolsaccharide mucolytic agents and uses thereof
|
|
WO2020252487A1
(en)
|
2019-06-14 |
2020-12-17 |
Children's Hospital Medical Center |
Rational therapeutic targeting of oncogenic immune signaling states in myeloid malignancies via the ubiquitin conjugating enzyme ube2n
|
|
JP7695232B2
(ja)
|
2019-09-18 |
2025-06-18 |
武田薬品工業株式会社 |
ヘテロアリール血漿カリクレインインヒビター
|
|
ES2987744T3
(es)
|
2019-09-18 |
2024-11-18 |
Takeda Pharmaceuticals Co |
Inhibidores de calicreína plasmática y usos de los mismos
|
|
WO2021211938A1
(en)
|
2020-04-17 |
2021-10-21 |
Shire Human Genetic Therapies, Inc. |
Solid forms of inhibitors of plasma kallikrein
|
|
ES3035604T3
(en)
|
2020-04-17 |
2025-09-05 |
Takeda Pharmaceuticals Co |
Forms and compositions of inhibitors of plasma kallikrein
|
|
BR112023018619A2
(pt)
|
2021-03-17 |
2023-11-28 |
Takeda Pharmaceuticals Co |
Inibidores de heteroaril de calicreína plasmática
|
|
JP2024512497A
(ja)
|
2021-03-17 |
2024-03-19 |
武田薬品工業株式会社 |
血漿カリクレインの阻害剤
|
|
WO2022197789A1
(en)
|
2021-03-17 |
2022-09-22 |
Shire Human Genetic Therapies, Inc. |
Polycyclic inhibitors of plasma kallikrein
|
|
JP2024510503A
(ja)
|
2021-03-17 |
2024-03-07 |
武田薬品工業株式会社 |
血漿カリクレイン阻害剤
|
|
CN117396473A
(zh)
|
2021-03-17 |
2024-01-12 |
武田药品工业株式会社 |
血浆激肽释放酶的咪唑并吡啶基抑制剂
|
|
IL309653A
(en)
|
2021-08-06 |
2024-02-01 |
Celgene Corp |
Composition and methods for selective degradation of transgenic proteins
|
|
JP2025526212A
(ja)
|
2022-07-21 |
2025-08-13 |
アンティバ バイオサイエンシズ インコーポレイテッド |
Hpv感染症及びhpv誘発性新生物の治療用の組成物及び剤形
|
|
WO2024040241A1
(en)
|
2022-08-19 |
2024-02-22 |
Viracta Therapeutics, Inc. |
Pharmaceutical formulations, processes for preparation, and methods of use
|
|
JP2025531207A
(ja)
|
2022-09-15 |
2025-09-19 |
武田薬品工業株式会社 |
遺伝性血管性浮腫の処置のための血漿カリクレイン阻害剤としてのn-((イソキノリン-6イル)メチル)-1h-ピラゾール-4-カルボキサミド誘導体
|